Vactosertib research paper is published in ‘Cancers’, an international academic journal indexed in SCIE
Dec 20, 2022
Discovered therapeutic implication of the Vactosertib combination treatment for dependency on the TGF-β pathways that were enriched in desmoid tumors
MedPacto (CEO Seong-jin Kim), a genome-based drug discovery and a clinical-stage biotechnology company, announced that the research paper on Vactosertib, a TGF-β receptor inhibitor, was published in the prestigious peer-reviewed international academic journal, Cancers (Impact Factor 6.575) on the 20th.
The research on therapeutic implications of TGF-β Pathway in desmoid tumors based on comprehensive molecular profiling and clinicopathological properties was conducted by the joint research team of MedPacto and Professor HyoSong Kim in Severance Hospital.
Based on the analysis of desmoid tumor samples from patients, the research team has discovered the enriched TGF-β signaling pathways in desmoid tumors compared with other sarcomas validating that the inhibition of the TGF-β signaling pathway is useful as a potential treatment for patients with desmoid tumors.
The research team also demonstrated that the Vactosertib combination treatment with Imatinib is more effective for tumor suppression while decreasing the survival rate of the desmoid tumor cell than monotherapy. Notably, after 11 months of co-administration with Vactosertib the tumor size of the desmoid patient was significantly decreased.
Desmoid tumor, also known as aggressive fibromatosis, is a rare disease for which the primary option for treatment is surgery. Although Imatinib is evaluated to be a treatment option for severe cases, because of its partial success with a low response rate, there is an urgent need for new treatment options.
MedPacto presented its clinical result of the phase 1b trial of the Vactosertib combination therapy with Imatinib, showing no tumor progression in all patients for six months resulting in a 100% progression-free survival(PFS) rate, at the American Society of Clinical Oncology (ASCO) in 2020.
“It has been scientifically confirmed that the TGF-β signaling pathways are significantly enriched in desmoid tumors,” “Although we withdrew our study in desmoid tumors following our ‘concentrating on a selected few pipelines’ strategy, this research paper has confirmed the clinical efficacy of the Vactosertib in patients with desmoid cancer” stated a MedPacto representative.